How Trikafta moves through the body in cystic fibrosis
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks at how the medicine elexacaftor/tezacaftor/ivacaftor (often called Trikafta) works in the body in people with cystic fibrosis. It helps doctors understand the right dose and how the drug is processed, which may improve treatment for children and adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cystic fibrosis
- You have at least one F508del mutation (a common genetic change)
- You are aged 6 years or older
- You have been taking the combination drug elexacaftor/tezacaftor/ivacaftor for at least 8 days
- You are not pregnant or breastfeeding
- You are not taking certain interacting medications that could affect the study drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the drug Trikafta (also called Kaftrio) works in children aged 2 to 17 with cystic fibrosis. The goal is to learn how the body processes the medicine so doctors can find the best dose.
This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.
This study looks at how the triple combination therapy (elexacaftor/tezacaftor/ivacaftor, or ETI) affects your body's metabolism, epigenetics, and gut bacteria in people with cystic fibrosis. It aims to understand the broader health benefits of this treatment.
This study measures how antibiotics are processed by the body in people with cystic fibrosis who are taking a combination drug called elexacaftor/tezacaftor/ivacaftor (ETI). Understanding this helps doctors prescribe the right antibiotic doses for patients on this newer treatment.
This study is looking at how a new combination medicine (Trikafta) affects the lungs and gut in people with cystic fibrosis who carry the DeltaF508 mutation. It aims to understand how the medicine works in the body.
This study tests how starting Trikafta affects exercise ability and breathing in adults with cystic fibrosis. You may be asked to do supervised breathing and exercise tests to see if Trikafta helps your lung function and stamina.
Hear when a new Cystic Fibrosis (CF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.